CD274 and neoplasm: ,4,7 Similarly, post hoc analyses of data from prospective randomized trials show that tumor mutational burden correlates well with benefit from PD-L1 inhibitor monotherapy, but loses its predictive ability in case of chemo-immunotherapy.32